Radiological evaluation of neo-adjuvant endocrine therapy in hormone-receptor positive early breast cancer

by Blok, E.J., Charehbili, A., Kroep, J.R., Seynaeve, C.M., Velde, C.J.H. van de, Kuppen, P.J.K.
Published 2016

Genetic variation in CYP19A1 and response to exemestane: Survival in early breast cancer in the Dutch TEAM trial

by Houtsma, D., Fontein, D., Wessels, J.A.M., Seynaeve, C.M., Velde, C.J.H. van de, Nortier, J.W.R., Guchelaar, H.J., Gelderblom, H.
Published 2012

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer: Updated results from the TEAM trial neuropsychological side study

by Kieffer, J.M., Small, B.J., Seynaeve, C., Boogerd, W., Kranenbarg, E.M.K., Velde, C.J. van de, Schagen, S.B.
Published 2015

Dynamic prediction in early breast cancer - feasibility of a novel prediction model in postmenopausal, endocrine sensitive breast cancer patients

by Fontein, D., Grand, M.K., Nortier, J.W.R., Seynaeve, C., Kranenbarg, E.M.K., Dirix, L., Velde, C.J.H. van de, Putter, H.
Published 2014

Age Specific Competing Mortality In Breast Cancer Patients - a TEAM Study Analysis

by Markopoulos, C., Water, W. van de, Putter, H., Seynaeve, C., Hasenburg, A., Rea, D., Vannetzel, J.M., Paridaens, R., Velde, C.J.H. van de, Jones, S.
Published 2011

DISTANT RECURRENCES AT MEDIAN OF 5-YEARS AMONG 9.779 POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE EARLY BREAST CANCER TREATED ON THE TEAM TRIAL OF ADJUVANT ENDOCRINE THERAPY

by Nortier, H., Hille, E., Rea, D., Seynaeve, C., Hasenburg, A., Vannetzel, J., Dirix, L., Markopoulos, C., Velde, C. van de, Jones, S.
Published 2010

Baseline comprehensive geriatric assessment to predict for toxicity of single-agent chemotherapy in elderly metastatic breast cancer patients: Results from the OMEGA study of the D...

by Hamaker, M., Seynaeve, C.M., Wymenga, M., Tinteren, H. van, Nortier, J.W.R., Maartense, E., Groot, S. de, Smorenburg, C.H.
Published 2012

Comparison of immunohistochemical residual risk panels to predict risk in early breast cancers treated with endocrine therapy

by Stephen, J., Murray, G., Cameron, D., Thomas, J., Kunkler, I., Jack, W., Kerr, G., Piper, T., Brookes, C., Rea, D., Velde, C. van de, Hasenburg, A., Markopoulos, C., Dirix, L., Seynaeve, C., Bartlett, J.
Published 2015

Does androgen receptor (AR) expression impact on residual risk? A TEAM pathology study

by Bartlett, J.M.S., Brookes, C.L., Yan, F.J., Quintayo, M.A., Bayani, J., Starczynski, J., Velde, C.J.H. van de, Hasenburg, A., Kieback, D.G., Markopoulos, C., Dirix, L., Seynaeve, C., Rea, D.W.
Published 2015

Time dependence of biomarkers: Non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer

by Stephen, J., Murray, G., Cameron, D., Thomas, J., Kunkler, I., Jack, W., Kerr, G., Piper, T., Brookes, C., Rea, D., Velde, C. van de, Hasenburg, A., Markopoulos, C., Dirix, L., Seynaeve, C., Bartlett, J.
Published 2015

Genetic variation in CYP19A1 and occurrence of adverse events in exemestane treatment with early breast cancer patients in the Dutch TEAM trial

by Houtsma, D., Fontein, D., Straaten, T. van der, Baak-Pablo, R., Wessels, J.A.M., Seynaeve, C., Velde, C.J.H.V. de, Nortier, J.W.R., Gelderblom, H., Guchelaar, H.J.
Published 2013

Specific Adverse Events and Outcome in Hormone Receptor Positive Breast Cancer Patients on Endocrine Therapy - a TEAM Study Analysis

by Water, W. van de, Hille, E.T.M., Hadji, P., Markopoulos, C., Seynaeve, C., Hasenburg, A., Dirix, L., Rea, D., Jones, S.E., Velde, C.J.H. van de
Published 2011

The contribution of self-esteem and self-concept in psychological distress in women at risk of hereditary breast cancer

by Heijer, M. den, Seynaeve, C., Vanheusden, K., Duivenvoorden, H.J., Vos, J., Bartels, C.C.M., Menke-Pluymers, M.B.E., Tibben, A.
Published 2011

Distress in partners of high-risk women undergoing breast cancer surveillance

by Heijer, M. den, Vanheusden, K., Seynaeve, C., Duivenvoorden, H.J., Dooren, S. van, Bartels, K.C.M., Menke-Pluijmers, M.B., Tibben, A.
Published 2010

Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches

by Christiansen, J., Bartlett, J.M.S., Gustavson, M., Rimm, D., Robson, T., Velde, C.J.H. van de, Hasenburg, A., Kieback, D.G., Putter, H., Markopoulos, C., Dirix, L.Y., Seynaeve, C.M., Rea, D.
Published 2012

Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the TEAM pathology study

by Bartlett, J.M.S., Bloom, K.J., Robson, T., Lawton, T.J., Velde, C.J.H. van de, Ross, D.T., Seitz, R.S., Beck, R.A., Hasenburg, A., Kieback, D.G., Putter, H., Markopoulos, C., Dirix, L.Y., Seynaeve, C.M., Rea, D.
Published 2012

Age at diagnosis and breast cancer outcomes after ten years of follow up among postmenopausal women with hormone receptor positive breast cancer

by Derks, M.G.M., Water, W. van de, Bastiaannet, E., Putter, H., Craen, A.J.M. de, Seynaeve, C., Rea, D.W., Nortier, J.W.R., Liefers, G.J., Velde, C.J.H. van de
Published 2016

Effect of small tumor size (<= 2 cm) on outcome of node negative breast cancer in BRCA1-associated versus matched sporadic patients

by Akdeniz, D., Jager, A., Koppert, L.B., Deurzen, C.H.M. van, Schmidt, M.K., Devilee, P., Ausems, M.G.E.M., Collaborators, H., Seynaeve, C., Hooning, M.J.
Published 2013

Survival and contralateral breast cancer in CHEK2 1100deIC breast cancer patients: Impact of adjuvant chemotherapy

by Kriege, M., Jager, A., Hollestelle, A., Berns, E.M.J.J., Sieuwerts, A.M., Collee, J.M., Devilee, P., Hooning, M.J., Martens, J.W.M., Seynaeve, C.
Published 2013

Hormone receptor positive breast cancer in patients aged 75 years and older: Limited external validity of clinical trial results

by Water, W. van de, Kiderlen, M., Bastiaannet, E., Velde, C.J.H. van de, Westendorp, R.G.J., Seynaeve, C., Nortier, J.W.R., Craen, A.J.M. de, Liefers, G.J.
Published 2013